The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Cyclooxygenase Inhibition and Cardiovascular Risk
Abstract
Over the past several months clinicians have been con-fronted at an escalating rate with reports describing the risks of COX-2 inhibitors (coxibs). Information on this class of drugs appears not only in traditional medical journals and textbooks, but also on the Web sites of regulatory agencies, professional societies, and pharmaceutical manufacturers.1–9 An unusual, but noteworthy, aspect of the state of affairs is the high rate of reporting new findings and opinions (at times voiced in a strident tone) in the lay press.10–13 Understand-ably, patients are concerned about the potential risks associ-ated with their antiinflammatory medications, and now, either spontaneously or in response to a public health warning, call their healthcare professional with questions or arrive for an office visit armed with publicly accessed information they wish to discuss. Owing to the widespread use of antiinflammatory drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 3×
“Variables of note include (1) the risk”
BackgroundLeukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B., Dahlén, S.-E., Lindgren, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Basic and Clinical Pharmacology
Katzung, B. G. (1982) · Andalas University Repository (Andalas University) · Cited by 1,914
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Hawkey, C. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12154-2 · Cited by 1,173
Cited by
Writing Committee Members, Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K. L., Furberg, C. D., Johnson, D. A., Mahaffey, K. W., & Quigley, E. M. (2008) · Circulation · doi:10.1161/circulationaha.108.191087 · Cited by 843
Self-citationCamenzind, E., Steg, P. G., & Wijns, W. (2007) · Circulation · doi:10.1161/circulationaha.106.666800 · Cited by 818
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Self-citationJelic, S., Padeletti, M., Kawut, S. M., Higgins, C., Canfield, S. M., Onat, D., Colombo, P. C., Basner, R. C., Factor, P., & LeJemtel, T. H. (2008) · Circulation · doi:10.1161/circulationaha.107.741512 · Cited by 618
Using Recovery Modalities between Training Sessions in Elite Athletes: Does it Help?
Barnett, A. (2006) · Sports Medicine · doi:10.2165/00007256-200636090-00005 · Cited by 593
Gislason, G. H., Jacobsen, S., Rasmussen, J. N., Rasmussen, S., Buch, P., Friberg, J., Schramm, T. K., Abildstrom, S. Z., Køber, L., Madsen, M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.616219 · Cited by 447
The Comparative Safety of Analgesics in Older Adults With Arthritis
Solomon, D. H. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.391 · Cited by 416
Cardiovascular effects and safety of (non-aspirin) NSAIDs
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0366-z · Cited by 387
Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K. L., Furberg, C. D., Johnson, D. A., Mahaffey, K. W., Quigley, E. M., Harrington, R. A., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.002 · Cited by 385
Self-citationSolomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
COX-2 Inhibitors and Cardiovascular Risk
Funk, C. D., & FitzGerald, G. A. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318157f72d · Cited by 330
Seropian, I. M., Toldo, S., Van Tassell, B. W., & Abbate, A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.014 · Cited by 296
Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L., Fosbøl, E. L., Sørensen, R., Folke, F., Buch, P., Gadsbøll, N., et al. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.525 · Cited by 295
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.028 · Cited by 283
Self-citationMitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B., Lamm, D., O'Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 252
Aljofan, M., & Ding, H. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.21986 · Cited by 58
Turtle, E. J., Dear, J. W., & Webb, D. J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12032 · Cited by 48
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction
Jugdutt, B. I. (2007) · Circulation · doi:10.1161/circulationaha.106.675306 · Cited by 41
Cardiorenal Safety of OTC Analgesics
White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417751070 · Cited by 31
The Big Idea: the coxib crisis Iron, aspirin and heart disease risk revisited
Sullivan, J. L. (2007) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.100.7.346 · Cited by 3
Metadata
- Authors
- Antman, E. M., DeMets, D., & Loscalzo, J.
- Venue
- Circulation
- Published
- 2005-08-02
- Volume
- 112
- Issue
- 5
- Pages
- 759-770
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2014184499
- Cited by
- 282
- References
- 75
- FWCI
- 17.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.